

Index

- A waves, 148–149
 AANEM. *See* American Association of Neuromuscular and Electrodiagnostic Medicine
 abductor pollicis brevis (APB), 318
 aberrant reinnervation, 223
 abnormal RNSS, 156
 absolute abnormal, 284
 absolute refractory period, 58–59
 AC. *See* alternating current
 accessory deep peroneal nerve, 269–270
 accommodation, 59
 acetate, 69
 acetylcholine (ACh), 68
 binding, 70–71
 exocytosis and, 69
 release, 71–72
 in synaptic space, 69
 synthesized, 69
 vesicles, 69, 71–72, 152–153
 acetylcholine receptors (AChR), 152, 200–201
 in LEMS, 253
 in myasthenia gravis, 252
 acetylcholinesterase (AChE), 69
 ACh. *See* acetylcholine
 ACh receptors (AChRs), 68–70
 AChE. *See* acetylcholinesterase
 AChRs. *See* acetylcholine receptors
 acquired axon loss polyneuropathies, 247–248
 acquired demyelinating polyneuropathies, 248–250
 actin, 74
 action at a distance, 7
 action potential (AP) generation, 59
 action potential (AP) propagation, 61
 antidromic, orthodromic conduction in, 92–93
 block, 124
 conduction velocity of, 62–63
 toward E1 electrode, 102
 in excitation-contraction coupling, 74
 length constant in, 125
 of myelin, 61–63
 physiologic, 93
 safety factor of, 125–126
 saltatory conduction in, 64
 speed, 62–65, 123–124, 132
 action potentials (AP), 34, 49, 59.
 See also absolute; compound muscle action potential; motor unit action potential; muscle fiber APs; relative refractory period; sensory nerve action potential
 duration of, 63–64
 of F wave, 146
 focal axon loss and, 124
 focal demyelination and, 123–124
 of nerve fibers, 99–100, 111
 of recording electrode, 90–91
 activation gate, of VGNC, 258
 activation phase
 of MUAP assessment, 193–194
 of needle EMG, 173, 235
 activation time, of muscle, 107
 active electrode, 87–88. *See also* bipolar recordings; E1 electrode; referential recordings
 active release zones, 68
 acute compression, 229–230
 acute inflammatory demyelinating polyradiculoneuropathy (AIDP), 249
 acute poliomyelitis, 237
 ADC. *See* analog-to-digital converter
 adductor pollicis muscle, 264–265
 adenosine monophosphate (AMP), 78
 adenylate kinase, 78
 adhesive surface recording electrodes, 89
 ADP, 75–76, 78
 age-related issues
 in NCS, 260–261
 in needle EMG, 261
 as pitfalls, 260–261
 agrin, 70
 AHCs. *See* anterior horn cells
 AIDP. *See* acute inflammatory demyelinating polyradiculoneuropathy
 aliasing, 42
 alkaline batteries, 11
 alpha gamma coactivation, 77
 ALS. *See* amyotrophic lateral sclerosis
 alternating current (AC), 14, 23
 cycle of, 24–25, 27
 in magnetic field, 26–28
 Ohm's law on, 23
 reversals in, 23, 36
 voltage in, 23–24
 alternating current (AC) signal
 of 60 Hz power artifact, 276–278
 in capacitors, 36–37
 dangers of, 290–291
 in high pass filter, 38
 in low pass filter, 38
 quantification of, 24–26
 aluminum, 27–28
 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), 290, 298, 306–307
 AMP. *See* adenosine monophosphate
 amphiphilic molecules, 49
 amplifiers
 ADC, DAC for, 45
 differential, 45–47
 for EMG machines, 45, 47
 gain on, 44
 inverting, 46
 monopolar, 44–45
 non-inverting, 46
 resistance, 44
 signal-to-noise ratio for, 47
 amplitude, 25
 absolutely, relatively abnormal, 102
 baseline-to-peak, 113
 body tissue and, 103
 CMAP, 103–104
 decrement, 100
 discrepancy, in DMCB, 130
 of fibrillation potentials, 185
 of H wave
 abnormal, 145
 in EMG laboratory, 144–145
 measurements of, 144–145
 low, peroneal-EDB, 285
 measurement of, 102–104
 of motor axons, 103
 of motor NCS, 100
 of motor response, 104, 135, 216
 of MUAP, 165, 173–176, 195
 negative AUC and, 104–105, 132
 peak-to-peak, 113
 response, very low, 284–285

Index

- amplitude (cont.)
 in sensory NCS, 113–114
 of sensory response, 135, 216
 synchrony and, 103
 of tibial response, 100
 amplitude values, 85
 amyotrophic lateral sclerosis (ALS), 132, 238
 analog filters, 40–41
 analog-to-digital converter (ADC), 41–43, 45
 anastomosis. *See also* Martin-Gruber anastomosis
 Berretini, 269
 in forearm, 268
 median-to-ulnar, 262
 Riche–Cannieu, 268–269
 ulnar-to-median, 268
 animal electricity (Galvani), 76
 anisotropic band, 75
 anodal block, 279
 anode, 11, 21–22, 43
 anode rotation, 273–275
 anomalous innervations, 262
 anterior horn cells (AHCs), 50, 68, 73, 79–80
 acute poliomyelitis and, 237
 disorders, 236–237
 in motor unit, 79–80, 162–163
 post-poliomyelitis syndrome and, 237–238
 SMA-3 and, 238–239
 antidromic conduction, 92–93
 antidromic sensory NCS, 111, 114–116
 AP. *See* action potentials
 APB. *See* abductor pollicis brevis
 apparent single fiber APs (ASFAPs), 206
 arborization point, 183
 area under the curve (AUC), 101
 DMCB and, 129
 negative, 104–105, 132
 ASFAPs. *See* apparent single fiber APs
 atomic number, 5
 atomic structure, in charge, 4–5
 atoms, 4–5, 8
 ATP, 75–76
 ADP to, 78
 of muscle fibers, 78
 atypically proximal MGA, 267
 AUC. *See* area under the curve
 axolemma, 50, 53
 axon, 50–51. *See also* distal; initial; myelin; proximodistal
 diameter, 62–63
 disruption
 in NCS, 137–138
 Wallerian degeneration in, 137–138
 motor, 103, 201
 terminals, 68
 axon loss, 123. *See also* acquired axon loss
 loss polyneuropathies; chronic motor axon loss
 approach to, in surgical intervention, 225–226
 conduction failure and, 131–132
 DMCB and, 214
 EDX features of, 248
 focal, 124, 202
 lesions, 215–216
 needle EMG study of, 215–216
 proximal lesion and, 147
 sensory response and, 135–136
 axonotmesis, 222
 axoplasm, 50
 B. *See* bel
 backfire
 of motor neurons, 146
 time, 146–147
 bandpass filter, 40
 bandwidth, of frequencies, 35
 basal firing rate, 165
 baseline train, 154
 baseline-to-peak amplitude, 113
 batteries
 alkaline, 11
 capacitors and, 21–22
 electrochemical cells and, 11
 lead-acid automotive, 11
 transistor, 11
 voltage in, 10–11, 18
 zinc-carbon, 11
 bel (B), 26
 Bell, Alexander Graham, 26
 belly-tendon method, 95–96
 Berretini anastomosis, 269
 bidirectional propagation, 74
 bilateral hand numbness and tingling, exercise, 332, 359
 EDX study conclusion in, 361
 EMG study conclusion in, 335
 NCS in, 332–334, 359–361
 needle EMG in, 334, 361
 bilateral lower extremity weakness, exercise, 428–429
 NCS in, 429
 needle EMG in, 429–430
 bilateral upper extremity weakness, exercise, 410, 421
 EDX study conclusion in, 412
 NCS in, 410–411, 421–422
 needle EMG in, 411–412, 422–424
 biological signals, unwanted, 46
 bipennate muscle, 80
 biphasic morphology, 95–96
 bipolar recordings, 88
 bits, 41
 bleeding
 in needle EMG, 295–296
 safety issues of, 295–296
 blink reflexes, 149–150
 blocking, 200, 205
 blood-nerve barrier, 66
 BMI. *See* body mass index
 body habitus-related issues
 gender in, 262
 as pitfalls, 261–262
 weight as, 262
 body mass index (BMI), 262
 body tissue, 103
 brachial plexus
 composition of, 242–243
 plexopathies of, 242–245
 preterminal nerves of, 242–243
 cable properties, 60
 calcinosis cutis, 299
 can't let-go currents, 291
 capacitance, 22
 DC circuit and, 33–34
 of membrane, 61–62
 total membrane, 60
 capacitive coupling, 45
 capacitive current, 21
 capacitive reactance, 36
 capacitors, 8. *See also* RC circuit
 AC signal in, 36–37
 batteries and, 21–22
 charge in, 21–23
 current and, 20–23
 DC signal in, 38–39
 defining, 21
 in EDX medicine, 20–21
 electrons and, 31
 filters and, 34, 36
 as frequency-dependent resistor, 38
 impedance and, 33–34
 RC circuit in, 37–39
 steady state response of, 33
 time constant in, 22, 60
 voltage in, 37
 capillaries, 66
 cardiac injury, 291
 carpal tunnel syndrome, 108, 126–127.
 See also bilateral hand numbness and tingling
 concomitant, MGA with, 265–266
 exercise, 324, 347, 351
 EDX impression in, 353–354
 EDX study conclusion in, 327, 349, 354
 NCS in, 324–326, 347–348, 351–353
 needle EMG in, 325–327, 348, 353
 cathode, 11, 21–22, 42–43, 273–274
 cauda equina, 241
 CDC. *See* Centers for Disease Control

- cell membrane, 49
 in EDX medicine, 49
 electrophysiological properties of, 49–50
 ions of, 49–50
 TMP and, 60
- cells, 49, 52. *See also* anterior horn cells
 electrochemical, 11
 excitatory, 57
 Schwann, 52, 123, 131
- Centers for Disease Control (CDC), 296
- central nervous system (CNS), 50–52, 76–77
- cervical plexus, 242
- change in distance, 107, 277
- change in time, 34, 107, 277
- charge
 atomic structure in, 4–5
 in capacitors, 21–23
 conductors, in flow of, 10
 conservation of, 36
 current, as flow of, 8–10, 21, 43
 current, as movement of, 8
 in electricity, 4–8
 electrostatic, 6–7
 negative, of electrons, 6
 separation, 22
 separation, voltage and, 22
 triboelectric effect in, 6
- chassis current, 291–292
- chemical denervation, 253
- chemical force, 54
- chemical synapses. *See* synapses
- choline, 69. *See also* acetylcholine
- choline acetyltransferase, 69
- chronic compression, 230–231
- chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 249–250
- chronic motor axon loss (CMAL), 320
- chronodispersion, 147
- CIDP. *See* chronic inflammatory demyelinating polyradiculoneuropathy
- circuit
 breaker, main, 29
 closed, 14
 DC in, 14, 33–34
 EMF in, 13
 loop, 18
 open, 14–15
 parallel DC, 18–20
 resistance of, 15–16, 19–20
 series, 13–14
 series DC, 14–18
 short, 15
 switches in, 15
 voltage in, 10, 17
- clean signal, 46
- clinical
 bias, as pitfall, 285
 features
 of fasciculation potentials, 189
 of lesions, 214
 grading, of lesion severity, 215
 information, collected by EDX provider, 309
- closed circuit, 14
- CMAL. *See* chronic motor axon loss
- CMAP. *See* compound muscle action potential
- CMRR. *See* common mode rejection ratio
- CNS. *See* central nervous system
- coaxial cable, 31
- collateral sprouting, 183
 motor response normalization through, 132–133
 reinnervation via, 195–196, 201, 218–220
- common mode rejection ratio (CMRR), 47
- common signal, 47
- compartment syndrome, 232
- complete interference pattern, 196
- complex repetitive discharges (CRDs), 192–193
- compound muscle action potential (CMAP), 95–96, 103–106
 H wave as, 144
 median, 201
 SNAP and, 135
- compression injuries, 228–229
 acute, 229–230
 chronic, 230–231
- concentric needle electrodes, 206–207, 277
- concentric needle recording electrodes, 179–180
- conceptual pitfalls, 282–286
- conductance, 19
- conduction. *See also* demyelinating conduction block;
 demyelinating conduction slowing; nerve; proximal;
 saltatory conduction; transient axonal conduction block
 antidromic, orthodromic, 92–93
 continuous, 63
 ephaptic, 192–193
 failure, axon loss and, 131–132
 proximal, 147
 slowing, focal demyelinating, 126
 time, of muscle fibers, 107
 values, 118
 volume, 90–92
- conduction block, 216
 pattern, of MGA, 267
- transient axonal, 131–132, 216
- conduction velocity, 62–64
 of forearm, 108, 126–127
 latency and, 132
 measurement of, 107–108
 nerve, 107
 in proximal stimulation site, 108
 in sensory NCS, 114, 118–119
 time of, 107
- conductors, 8
 copper as, 10
 in flow, of charge, 10
 metals as, 9
- cone, lateral surface area of, 180
- connective tissue, 65–66, 224
- conservation, of charge, 36
- constant current stimulators, 44, 272
- constant voltage stimulators, 44, 272
- consult. *See also* the encounter
 reviewing, 307–308
 scheduling, 308
- continuous conduction, 63
- continuous propagation, 61
- contractures, 189
- conventional current, 9
- cool limbs, studying
 MUAP of, 260
 NCS of, 258–259
 needle EMG for, 260
 pitfalls of, 257–260
 RNSS of, 259–260
- cooperative binding, 70
- copper, 9–10
- correction factors, 259
- corticobulbar tract, 50
- corticospinal tract, 50
- Coulomb's inverse-square law, 7
- CPS. *See* cycles per second
- cramp potentials, 188–190
- CRDs. *See* complex repetitive discharges
- creatine kinase, 78
- current. *See also* alternating current;
 direct current; Kirchhoff's current law
 available, required, 125
 capacitive, 21
 capacitors and, 20–23
 chassis, 291–292
 conventional, 9
 displacement, 21
 dividers, 19
 in electricity, 8–10
 electron, 9
 as flow, of charge, 8–10, 21, 43
 intensity of, 293–294
 leading source, 91
 let-go, can't let-go, 291
 limits, safe, 293

Index

- current. (cont.)
 loop, 293
 as movement, of charge, 8
 Ohm's law and, 15
 pathway, 291
 sources, 91–92
 stimulators and, 43–44
 trailing source, 91
 transmembrane, 60
 transverse, 62
 cutaneous domain, 134
 cutoff frequency, 37, 39–40
 cycles per second (CPS), 23
 cytoplasm, 50
- DAC. *See* digital-to-analog converter
 dark matter, 4
 dB. *See* decibel
 DC. *See* direct current
 decibel (dB), 26
 decreased insertional activity, 184
 degeneration. *See also* Wallerian degeneration
 distal axon, 131
 distal stump, 124
 of NMJ, 137
 delayed repair, 231
 demyelinating conduction block (DMCB), 123–125
 acute compression and, 229–230
 amplitude discrepancy in, 130
 AUC and, 129
 axon loss and, 214
 chronic compression and, 230
 focal, 128–131, 202
 lesion, 202
 MGA and, 263–264
 neurapraxia and, 221–222
 proximal lesion and, 147
 proximally-located, 201
 spiral groove and, 128
 stimulation sites, 130
 ulnar motor response and, 129
 demyelinating conduction slowing (DMCS), 123–126, 214
 acute compression and, 229–230
 chronic compression and, 230
 focal, 126–127, 202
 nonuniform, 127–128
 proximal lesion and, 147–148
 uniform, 126–127
 demyelination, 123. *See also* acquired demyelinating
 polyneuropathies; focal demyelination
 focal, 123–126
 identifying, 284–285
 depolarization. *See also* endplate potential
 of membrane, 63
 phase, 57
 postsynaptic membrane, 71–72
 repolarization and, 57–58
 by stimulator, 43–44
 VGNCs in, 61
 depolarization threshold, 54
 desired signal, 33, 35, 45–46
 diabetic neuropathic cachexia, 420–421
 difference, in signal, 46
 differential amplifiers, 45–47
 differential signal, 87
 diffuse numbness and weakness, exercise, 403–404
 EDX conclusion in, 406–407
 NCS in, 404–405
 needle EMG in, 405–406
 diffuse upper extremity weakness and sensory loss, exercise, 460
 EDX conclusion in, 463
 NCS in, 460–461
 needle EMG in, 461–462
 digital filters, 41
 digital sensory NCS, 114
 digital signal, 35
 digital-to-analog converter (DAC), 41–43, 45
 direct current (DC), 14. *See also* series DC circuits
 in circuit, 14, 33–34
 circuits, parallel, 18–20
 signal
 in capacitors, 38–39
 danger of, 290–291
 discharge time, 125
 discrete interference pattern, 196
 disintegration, of motor unit, 169
 displacement current, 21
 disposable gloves, 296–297
 distal axon degeneration, 131
 distal axon sprouting. *See* collateral sprouting
 distal latency
 CMAP and, 105–106
 measurement of, 105–106
 time, 106–107
 distal left upper extremity sensory and motor abnormalities, exercise, 442
 EDX study conclusion in, 445
 NCS in, 442–444
 needle EMG in, 444–445
 distal muscles, 154
 distal sprouting, 220
 distal stump, 134
 distal stump degeneration, 124
 distance, measurement of, 278–279
 DMCB. *See* demyelinating conduction block
- DMCS. *See* demyelinating conduction slowing
 doping, 42
 dorsal root ganglia (DRG), 51, 133–134, 138, 140, 241
 drift velocity, 9
 duration, of MUAP. *See* motor unit action potential
 dysmyelinating disorders, 250–251
- E1 electrode. *See also* interelectrode distance
 APs propagating toward, 102
 misplacement, in sensory NCS, 112
 in motor NCS, 126
 positive dip of, 97–98
 in sensory NCS, 113
 E2 electrode
 improper placement of, 97
 in motor NCS, 126
 needle for, 98
 placement of, 96–97
 in sensory NCS, 113
 early recruitment, 169, 199–200
 early repair, 231
 ECF. *See* extracellular fluid
 EDB. *See* extensor digitorum brevis
 EDX. *See* electrodiagnostic
 efflux, 54
 Einthoven galvanometer, 85
 electric fields, 31
 electric power
 single-phase, 28
 three-phase, 28–29
 electrical force, 54
 electrical injury
 general guidelines, to avoid, 293
 ground in, 292–293
 safety issues and, 290–293
 electricity
 charge in, 4–8
 current in, 8–10
 in EDX, 3
 history of, 4
 household, 26–30
 Ohm's law in, 12–13
 resistance in, 11–12
 static, 4
 as term, 4
 voltage in, 10–11
 electrochemical cells, 11
 electrochemical force, gradient, 54
 electrodes. *See also* E1 electrode; E2 electrode; motor NCS; needle electrode; needle recording electrodes; surface recording electrodes
 active, 87–88
 adhesive surface recording, 89

- ground, 46
- history of, 86–87
- impedance and, 89, 270
- inactive, 87–88
- nonadhesive, 89
- recording
 - APs and, 90–91
 - in sensory NCS, 115
- reference, 87
- stimulating, 93–94
- surface stimulating, 88
- electrodiagnostic (EDX) abnormalities, with nonorganic lesions, 318–319
- electrodiagnostic (EDX) assessment
 - issues, connective tissue and, 224
- electrodiagnostic (EDX) examination
 - late responses in, 141
 - of plexopathies, 241–242
 - sensory NCS in, 111
 - timing of, 303–304
 - transmission, of infection in, 296
- electrodiagnostic (EDX) features
 - of axon loss, 248
 - of fasciculation potentials, 189–190
 - of lesions, 214
 - of myotonic potentials, 191
- electrodiagnostic (EDX) grading, of
 - lesion severity, 215–216
- electrodiagnostic (EDX) laboratory
 - negative AUC in, 105
 - pathophysiology in, 105
 - safety issues in, 290
- electrodiagnostic (EDX)
 - manifestations, of myopathies, 254
- electrodiagnostic (EDX) medicine
 - APs in, 49
 - capacitors in, 20–21
 - cell membrane in, 49
 - electricity in, 3
 - focal demyelination in, 124
 - formulas in, 4
 - voltage in, 10
- electrodiagnostic (EDX) practitioner,
 - skin preparation by, 44–45
- electrodiagnostic (EDX) provider, 236
 - clinical information collected by, 309
 - filters and, 34–35
 - in peripheral nerve injuries, 213
 - pitfalls of, 257, 270
 - RC circuits and, 38
- electrodiagnostic (EDX) report,
 - 312–313
- electrodiagnostic (EDX) studies. *See also* consult; the encounter
 - components, order of performance and, 305–306
 - dependent *versus* independent, 303
 - explaining, to patient, 308–309
 - findings of, 319
 - of focal neuropathies, 246–247
 - initial, 319
 - needle EMG in, 161–162
 - nerve fiber in, 52
 - preoperative *versus* postoperative, 354
 - on radiculopathies, 240
 - reduced temperature in, 258–260
 - signals in, 34–35
 - supervision of, 306–307
 - timing of, 216
 - variation, among EMG laboratories, 305
- electrodiagnostic (EDX) technique,
 - RNS as, 152–153
- electrodiagnostic (EDX) testing, 33
 - as extension, of neurological examination, 302
 - filters in, 34–35
 - lesion localization in, 317–318
 - limitations of, 304–305
 - for peripheral neuropathies, 246
 - for polyneuropathies, 248
 - of radiculopathies, 241
 - for sensory neuronopathies, 251
 - utility of, 304
- electrolyte, 11
- electromagnetic field, 31
- electromagnetic induction, 23, 45
- electromagnetic radiation, 31
- electromagnetic waves, 9
- electromotive force (EMF), 10
 - in circuit, 13
 - potential difference in, 10
 - voltage and, 12
- electromyography (EMG)
 - abnormalities
 - APB and, 318
 - of FDI, 317
 - disease, 170–171
- electromyography (EMG) laboratory. *See also* needle EMG
 - antidromic sensory NCS in, 116
 - EDX study variation among, 305
 - envelope pattern in, 154
 - F wave studies in, 148
 - facilitation in, 145
 - filters in, 41
 - H wave amplitude in, 144–145
 - high frequency RNSS in, 157
 - latency in, 116
 - NCS in, 85, 93
 - normal control values in, 282
 - sensory NCS in, 113
 - standard, nonstandard motor NCS in, 101
 - 20:20 rule in, 100
 - voltage in, 46
- electromyography (EMG) machine
 - ADC, DAC in, 42
 - amplifier for, 45, 47
 - desired, undesired signal in, 33
 - isolated power systems and, 292
 - limitations of, 144
 - maximum stimulation in, 276
 - onset, peak latency in, 117
 - pitfalls of, 276
 - sensitivity of, 283
 - stimulator in, 44
 - time cursors on, 285–286
 - on time difference, 277–278
 - vertical resolution of, 283
- electron current, 9
- electrons, 4–5
 - capacitors and, 31
 - movement of, 8–9
 - negatively charged, 6
 - Pauli exclusion principle and, 5–6
 - in static electricity, 7–8
- electrostatic charge, 6–7
- electrostatic force, 31
 - protons and, 7
 - strength of, 7
- electrotonic properties, 60
- elements, 4
- EMF. *See* electromotive force
- EMG. *See* electromyography
- the encounter
 - activities occurring after, 312
 - activities occurring during
 - limbs studied in, 309
 - NCS performed first, 309
 - needle EMG studies in, 309–312
 - activities occurring immediately before, 309
 - consult before
 - reviewing, 307–308
 - scheduling, 308
 - verbal informed consent in, 308–309
- endoneurial tube, 65
- endoneurium, 65
- endplate, 68, 70. *See also* miniature endplate potential
 - activity, in needle EMG, 171
 - region, 95
 - spikes, 172
- endplate potential (EPP), 71–72. *See also* miniature endplate potential
- end-to-end repair, 226
- end-to-end suturing, 226–227
- envelope pattern, 154
- ephaptic conduction, 192–193
- epineurial repair, 227

Index

- epineurium, 65–66
 EPP. *See* endplate potential
 EPSPs. *See* excitatory postsynaptic potentials
 equilibrium potential, 55–56. *See also* Nernst equation
 excessive stimulation, 275–276
 excitation-contraction coupling
 AP propagation in, 74
 sarcomere in, 74–76
 sarcoplasmic reticulum in, 74
 excitatory cells, 57
 excitatory postsynaptic potentials (EPSPs), 61, 165
 exhaustion, postexercise, 155–156
 exocytosis, 69
 extensor digitorum brevis (EDB), 285
 extracellular fluid (ECF), 53, 56–57
 extrafusal muscle fiber innervation, 76
 extrafusal muscle fibers, 53
- F wave, 146
 APs of, 146
 latency, 146–148
 minimal latency of, 147
 physiology, technique of, 146–147
 repeater, 147
 studies, in EMG laboratories, 148
 utility of, 147–148
- facilitation
 in EMG laboratory, 145
 postexercise, 155–156
- farad, 22
- fascicles, 65–66
- fascicular repair, 227
- fascicular sparing, 318
- facilitation potentials, 188–189
 clinical features of, 189
 EDX features of, 189–190
 grading of, 190
 myogenic, 189
 sites of origins of, 189
 waveform morphology of, 189–190
- FDA. *See* Food and Drug Administration
- FDI. *See* first dorsal interosseous muscle
- FDP. *See* flexor digitorum profundus
- fibrillation potentials, 185. *See also* needle EMG
 amplitude of, 185
 duration, morphology of, 185–187
 firing frequency of, 186–187
 insertional positive sharp waves in, 188
 of myopathies, 254–255
 positive sharp wave form of, 186, 188
 quantification of, 187
 specificity, utility of, 187–188
- spike form of, 185–186
 time to appearance of, 187
- filtering
 high frequency, 280–281
 issues, 279–281
 low frequency, 280
 in sensory NCS, 119–120
- filters, 33
 analog, 40–41
 arrangements of, 40–41
 bandpass, 40
 capacitors and, 34, 36
 cutoff frequency for, 39–40
 digital, 41
 EDX providers and, 34–35
 in EMG laboratory, 41
 high pass, 38, 40
 low pass, 38, 40
 notch, 40–41
 RC circuits in, 35–36
 stopband, 40
 transition band in, 39
- final common path, 76
- firing frequency
 of fibrillation potentials, 186–187
 of motor units, 165
 of MUAP, 165–168
- first dorsal interosseous (FDI) muscle
 EMG abnormalities of, 317
 MGA to, 264–267
- fixed distances, landmarks, 116–117
- flashover, 28
- flexor digitorum profundus (FDP), 317
- flow
 of charge, 8–10, 21, 43
 hole, 9
 ionic, 53–54, 56
 of water, 12–14, 18–19
- FM. *See* frequency modulation
- focal axon loss, 124, 202
- focal demyelination, 123–124. *See also* demyelinating conduction
 slowing
 conduction, 126
 in NCS, 137–138
 pathology of, 125–126
 in sensory NCS, 134
- focal DMCB, 128–131, 202
- focal DMCS, 126–127, 202
- focal neuropathies, 246–247
- Food and Drug Administration (FDA), 290
- force generation, motor unit, 79
- forearm
 anastomosis in, 268
 conduction velocity, 108, 126–127
- formulas, in EDX medicine, 4
- frequencies
 bandwidth of, 35
 cutoff, 37, 39–40
 ideal sampling, 283
 onset, 165–166
 recruitment of, 165–166
- frequency modulation (FM), 40
- frequency-dependent resistors, 38
- frequency-independent resistors, 36
- full interference pattern, 168
- fusimotor neurons, 76
- gain
 on amplifiers, 44
 sensitivity and, 282
- Galvani, Luigi, 9–10, 76
- galvanism, 9
- gamma gain, 77
- gases, 9
- Gasser, Herbert, 62
- gated ion channels, 50, 54, 57–58
- gender, 262
- generalized low motor normal sensory (GLMNS), 138
- generalized weakness. *See also* diabetic neuropathic cachexia
 exercise, 415–416
 diagnosis in, 420–421
 NCS in, 416–418
 needle EMG in, 418–420
- GLMNS. *See* generalized low motor normal sensory
- gloves, disposable, 296–297
- Goldman-Hodgkin-Katz voltage equation, 56
- GRDs. *See* grouped repetitive discharges
- grid, 27, 42
- ground. *See also* iso-grounds
 in electrical injury, 292–293
 electrode, 46
 loop current, 293
- grouped repetitive discharges (GRDs), 192–193
- H band, 75
- H reflex study, 142
 supine patient in, 142
 technique of, 142–143
 tibial nerve stimulation in, 142–144
- H wave, 142
 amplitude
 abnormal, 145
 in EMG laboratory, 144–145
 latency measurements of, 144–145
 as CMAP, 144
 testing
 technical errors in, 143–144
 utility of, 145–146
- hand muscle innervation patterns, 269

- accessory deep peroneal nerve in, 269–270
 Berretini anastomosis in, 269
 head, 75
 Helmholtz, Herman von, 85
 Henneman size principle, 164
 hereditary dysmyelination, 250–251
 hereditary polyneuropathies, 250–251
 hertz (Hz), 23
 high frequency filtering, 280–281
 high frequency RNSS. *See* repetitive nerve stimulation studies
 high pass filter, 38, 40
 hinge, 75
 hole flow, 9
 horizontal resolution, 283
 household electricity, 26–30
 hyperpolarization, 57–58
 hypothalar eminence, MGA to, 263–264
 Hz. *See* hertz
- iatrogenic pneumothorax, 298–299
 ICF. *See* intracellular fluid
 ideal sampling frequencies, 283
 immediate release pool, 69
 impedance, 23
 in capacitors, 33–34
 electrodes and, 89, 270
 mismatch, 47, 270, 272
 between signal source, surface recording electrode, 286
 skin, 273
 inactivation gate, 258
 inactive electrode, 87–88. *See also* E2 electrode
 incomplete interference pattern, 196–197
 increased insertional activity, 184
 inductive coupling, 30
 inductors, 23–24
 indwelling medical devices
 NCS with, 294–295
 RNSS with, 295
 safety issues of, 293–295
 inert atoms, 8
 infection, transmission of
 disposable gloves, for preventing, 296–297
 in EDX examination, 296
 needle electrodes in, 297–298
 safety issues of, 296–298
 skin in, 298
 influx, 54
 infraclavicular plexus, 243–244
 inhibitory postsynaptic potentials (IPSPs), 61
 initial axon segment, 183
 initial positive phase, 91
- innervation. *See also* hand muscle innervation patterns
 anomalous, 262
 extrafusal muscle fiber, 76
 ratio, 51, 73, 195, 219
 zones, 103
 insertional activity
 decreased, 184
 increased, 184
 in needle EMG, 162, 170–171, 184, 235
 insertional positive sharp waves, 188
 insulators, 8–9
 intensity, of currents, 293–294
 interconnections, 27
 interelectrode distance, in sensory NCS, 120–121
 internal longitudinal current, 63
 internal neurolysis, 231
 internodal distance, 63
 internodal membrane segments, 63–64
 internodes, 52
 intervertebral foramina, 51
 intracellular fluid (ICF), 53, 56–57
 intrafusal muscle fibers, 53, 76
 intraspinal canal disorders, 51
 acute poliomyelitis as, 237
 AHC disorders and, 236–237
 ALS as, 238
 background anatomy of, 236
 Kennedy disease as, 239
 NCS in, 236
 post-poliomyelitis syndrome as, 237–238
 radiculopathies as, 239–241
 SMA-3 as, 238–239
 intussusception, 214
 inverting amplifier, 46
 ion channels, 53–55
 ionic current, 53–54
 ionic flow, 53–54
 ionic flux, 53–54
 ionotropic receptors, 68
 ions, 8. *See also* Nernst equation
 of cell membrane, 49–50
 flow of, 54, 56
 movement of, 56–57
 IPSPs. *See* inhibitory postsynaptic potentials
 ischemic injuries, 231
 iso-grounds, 46
 isolated electrical myotonia, 191
 isolated power systems, 292
 isotopes, 5
 isotropic bands, 75
- jiggle, 201, 206
 jitter, 200, 205
- concentric needle electrode for, 206–207
 potential, of muscle fiber APs, 205
 value, of muscle fiber APs, 205–206
 juxtaparanode, 52
- Kennedy disease, 239
 Keraunoparalysis, 290
 Kirchhoff's current law, 14–15, 36
 Kirchhoff's voltage law, 14
- Lambert test, 157–158
 Lambert-Eaton myasthenic syndrome (LEMS)
 background of, 253
 needle EMG study of, 253–254
 as NMJ disorder, 253–254
 RNSS for, 253
 routine NCS in, 253
 late fibers, 187
 late responses, in EDX examination, 141
 latency. *See also* onset latency
 conduction velocity and, 132
 in EMG laboratories, 116
 of F wave, 146–148
 measurements, of H wave, 144–145
 minimal, 147
 peak, 112, 117–118
 proximal, 105
 in sensory NCS, 116
 values, 118
 lateral surface area, of cone, 180
 LCDD. *See* light-chain deposition disease
 lead-acid automotive battery, 11
 leading source current, 91
 leading-off surface, 179
 leading-off surface area, of needle electrodes, 204
 leadwire, 45–46
 least resistance, 18
 left common peroneal neuropathy, 376–378
 left foot numbness and burning, exercise, 378
 EDX study conclusion in, 381
 NCS in, 378–380
 needle EMG in, 380–381
 left hand atrophy, exercise, 457
 EDX conclusion in, 460
 NCS in, 457–459
 needle EMG in, 459–460
 left hip pain, exercise, 335
 EMG conclusion in, 338
 NCS in, 335–337
 needle EMG in, 337–338

Index

- left upper extremity pain, tingling, and weakness, exercise, 439
 EDX examination conclusion in, 442
 NCS in, 439–441
 needle EMG in, 441–442
 left wrist drop, exercise, 455
 EDX conclusion in, 457
 NCS in, 455–456
 needle EMG in, 456–457
 LEMS. *See* Lambert-Eaton myasthenic syndrome
 length constant, 62, 125
 length-dependent polyneuropathies, 247
 Lenz's law, 23–24
 lesion
 acuteness, 214–215
 axon loss and, 215–216
 clinical, EDX features of, 214
 completeness, 225–226
 DMCB, 202
 localization
 in EDX testing, 317–318
 in NCS, 137, 140
 MUAP and, 202
 nonorganic, 318–319
 postganglionic, 140
 proximal, 147–148
 in sensory NCS, 134
 severity
 clinical grading of, 215
 EDX grading of, 215–216
 motor response value and, 217–218
 in needle EMG studies, 218
 sensory response value and, 218
 site, Wallerian degeneration at, 137–138
 stimulation above, 131
 stimulation below, 131
 let-go currents, 291
 Leyden jar, 4
 ligand-gated channels, 54, 68
 light-chain deposition disease (LCDD), 397
 lightning, 8
 limbs, studied, in NCS, 309. *See also* cool limbs, studying
 linear phase characteristic, 40–41
 liquids, 9
 LMN. *See* lower motor neurons
 load, 15, 18
 local potentials, 61
 local responses, 59–61
 localization. *See also* lesion
 point, 317
 of postganglionic lesions, 140
 regional, 317
 long duration MUAPs, 248
 longitudinal tubules, 74
 loop
 circuit, 18
 current, 293
 recorder, 294
 low frequency filtering, 280
 low frequency RNSS. *See* repetitive nerve stimulation studies
 low pass filter, 38, 40
 low voltage, 29
 lower back pain, exercise, 322, 367, 398
 EDX study conclusion in, 323, 370
 EMG conclusion in, 400
 NCS in, 322–323, 368, 398–399
 needle EMG in, 323, 368–369, 399–400
 lower motor neurons (LMN), 50, 76
 lower plexus, 243–244
 lumbosacral plexus
 NCS of, 245
 needle EMG study of, 245–246
 plexopathies of, 245–246
 M wave, 142, 276
 machine maximum stimulation, 276
 macro EMG, 204, 207–208
 macro MUAP, 208
 macroshock, 291
 magnetic field, 26–28, 31
 main circuit breaker, 29
 main reserve, 69
 maintenance of position, 235–236
 major surgical interventions, 226–227
 Martin-Gruber anastomosis (MGA), 262–263. *See also* anastomosis
 to adductor pollicis muscle, 264–265
 atypically proximal, 267
 with concomitant carpal tunnel syndrome, 265–266
 with concomitant ulnar neuropathy, 266–267
 conduction block pattern of, 267
 DMCB and, 263–264
 to FDI, 264–267
 to hypothenar eminence, 263–264
 proximal median motor response and, 266–267
 unrecognizable, 268
 mass number, 5
 maximal temporal recruitment, 168–169
 maximum response, to stimulus, 93
 MBFC. *See* medial brachial fascial compartment syndrome
 MCD. *See* mean consecutive difference
 mean consecutive difference (MCD), 205–207
 measurement
 of amplitude, 102–104
 of conduction velocity, 107–108
 of distal latency, 105–106
 of distance, 278–279
 errors, 277–279, 285–286
 of motor response, 101–102
 MUAP, 164
 of muscle fibers, 101–102
 needle EMG, 169–170
 of negative AUC, 104–105
 of negative phase duration, 109
 in sensory NCS, 112–113
 medial brachial fascial compartment (MBFC) syndrome, 478–479
 median CMAP, 201
 median-to-ulnar anastomosis, 262
 Medical Research Council (MRC), 215
 Medicare, 306
 membrane, 54–55. *See also* ion channels; postsynaptic; presynaptic; total membrane capacitance; transmembrane current; transmembrane potential
 capacitance of, 61–62
 depolarization of, 63
 MEPP. *See* miniature endplate potential
 metals, as conductors, 9
 MGA. *See* Martin-Gruber anastomosis
 microshock, 291
 MIDD. *See* monoclonal immunoglobulin deposition disease
 middle plexus, 243–244
 miniature endplate potential (MEPP), 71, 152, 171–172
 minimal latency, of F waves, 147
 missing relative abnormalities, 284
 mixed NCS, 93, 121–122
 mixed polyneuropathies, 250
 mixed signal, 37–38
 M-line, 75
 MMV. *See* moment-to-moment variability
 mobilization store, 69
 molecules, amphiphilic, 49
 moment-to-moment variability (MMV), 178, 200–201
 monoclonal immunoglobulin deposition disease (MIDD), 397
 mononeuropathies. *See* focal
 monopolar amplifiers, 44–45
 monopolar needle electrodes, 180
 motor axon
 amplitude of, 103
 loss, 201
 motor NCS, 85, 92, 95
 abbreviations for, 321

- advantages, disadvantages of, 132–133
 amplitude of, 100
 E1, E2 electrodes in, 126
 exercise, for sensorimotor
 dysfunction, 354–355
 focal demyelination and, 125–126
 needle EMG and, 138–140, 161–162, 201
 nerve stimulation in, 98–99
 PNS elements assessed by, 138–140
 proximal tibial motor response to, 100
 radiculopathies and, 239–240
 recording electrodes for, 95
 belly-tendon method and, 95–96
 biphasic morphology of, 95–96
 standard, nonstandard, 101
 temporal dispersion and, 131
 motor nerve branching, 51
 motor nerves, 85
 motor neurons, 50–51, 146
 motor point, of muscle, 95, 270–271
 motor response
 amplitude, 104, 135, 216
 in blink reflexes, 149
 low, nonpathological causes of, 202
 measurement of, 101–102
 normalization, through collateral sprouting, 132–133
 from spinal cord level, 138
 ulnar, 96–97, 129
 value of, lesion severity and, 217–218
 motor unit, 50, 124–125. *See also* non-myopathic motor unit
 disintegration disorders
 AHC and, 79–80, 162–163
 anatomy, physiology, 162–163
 disintegration disorders, 183
 disintegration of, 169
 firing frequency of, 165
 force generation, 79
 of muscle fibers, 73, 78–79
 recruitment, 164–169
 size, distribution of, 79–80
 types of, 78
 motor unit action potential (MUAP), 183
 amplitude, 165, 173–176, 195
 assessment
 activation phase of, 193–194
 in needle EMG, 162–163, 173, 183–184
 auditory characteristics of, 161
 of cool limbs, 260
 duration, 163–164, 175–177, 194–195, 240, 261, 281–282, 284
 firing frequency of, 165–168
 full interference pattern in, 168
 GRD of, 192
 lesions and, 202
 long duration, 248
 macro, 208
 maximal temporal recruitment in, 168–169
 measurements, 164
 MMV of, 178, 200–201
 morphology, grading, 320
 muscle fiber APs and, 132
 of myopathies, 254
 neurogenic, 130–131, 176, 218, 243–245
 neurogenic recruitment in, 168–169, 197–198, 243–245
 phases of, 177–178, 195
 recording, 179–180
 recruitment, 196–197
 in ALS, 238
 grading, 320
 in needle EMG, 165–166
 pattern, 162, 169
 ratio of, 166–167
 in UMN disorders, 235–236
 reinnervation via collateral sprouting in, 195–196
 reinnervation via proximodistal axon advancement, 196
 satellite potential and, 196
 stability, 178, 200–201
 of trapezius muscle, 299
 trigger line of, 176
 turns of, 177–178, 195
 voluntary activity in, 193–194
 movement
 of charge, 8
 of electrons, 8–9
 of ions, 56–57
 MRC. *See* Medical Research Council
 MUAP. *See* motor unit action potential
 multipennate muscle, 80
 muscle. *See also* first dorsal
 interosseous muscle; hand
 muscle innervation patterns;
 neural control, of muscle
 activation time, 107
 adductor pollicis, 264–265
 bipennate, 80
 contraction, 78–79
 distal, 154
 innervation ratios, 51, 73, 219
 lengthening, 77
 motor point of, 95, 270–271
 multipennate, 80
 in needle EMG, 162
 shortening, 77–78
 spindles
 anatomy of, 77
 physiology of, 77–78
 structural organization of, 73–74
 studied, in needle EMG, 310
 tissue transit time, 107
 tone, 77
 trapezius, 299
 unipennate, 80
 muscle fiber APs, 74, 99, 102–103, 132, 173–174
 concentric needle electrodes for, 206–207
 jitter value of, 205–206
 jittering potential of, 205
 SFEMG for, 204–205
 triggering potential of, 205
 muscle fibers, 76
 ATP of, 78
 conduction time, 107
 density of, 175–176
 extrafusal, 53
 intermingling, 51
 intrafusal, 53, 76
 measurement of, 101–102
 motor units of, 73, 78–79
 NMJ of, 80
 primary, secondary endings in, 77
 proximity of, 175–176
 types of, 79
 muscle-specific kinase (MuSK), 70
 myasthenia gravis, 152
 AChR in, 252
 background of, 252
 needle EMG study of, 253
 as NMJ disorder, 252–253
 RNSS in, 252–253
 routine NCS in, 252
 myelin, 52–53. *See also* demyelination;
 remyelination
 advantage of, 61–62
 in AP propagation, 61–63
 sheath, 123, 125
 myofibrils, 74
 myogenic fasciculation potentials, 189
 myokymia, 192–193
 myopathies, 132, 199–200
 EDX manifestations of, 254
 fibrillation potentials of, 254–255
 MUAP of, 254
 needle EMG and, 254
 myoplasm, 73
 myosin, 74–75
 myotome, spinal cord and, 138
 myotonia, 190–191. *See also*
 neuromyotonia
 myotonic potentials, 190–191
 EDX features of, 191
 in needle EMG studies, 191
 train of, 191
 NA. *See* neuralgic amyotrophy
 National Electrical Code, 29

Index

- NCS. *See* nerve conduction studies
- neck pain, exercise, 349, 364, 370, 432–433
- EDX study conclusion in, 373–374, 390, 435–436
- EMG conclusion in, 351, 367
- NCS in, 349–350, 364–366, 370–372, 387–389, 433–434
- needle EMG in, 350–351, 366–367, 372–373, 389–390, 434–435
- needle electrode, 98
- concentric, 206–207, 277
- jitter and, 206–207
- leading-off surface dimensions of, 204
- macro EMG, 207–208
- monopolar, 180
- recording surface, 277
- single-fiber, 204–205
- in transmission, of infection, 297–298
- needle EMG. *See also* electromyography
- abbreviations for, 321
- activation phase of, 173, 235
- age-related issues in, 261
- bleeding in, 295–296
- for cool limbs, 260
- in EDX studies, 161–162
- endplate
- activity in, 171
- spikes in, 172
- exercise
- for bilateral hand numbness, tingling, 334, 361
- for bilateral lower extremity weakness, 429–430
- for bilateral upper extremity weakness, 411–412, 422–424
- for carpal tunnel syndrome, 325–327, 348, 353
- for diffuse numbness, weakness, 405–406
- for diffuse upper extremity weakness, sensory loss, 461–462
- for distal left upper extremity sensory, motor abnormalities, 444–445
- for generalized weakness, 418–420
- for left foot numbness, burning, 380–381
- for left hand atrophy, 459–460
- for left hip pain, 337–338
- for left upper extremity pain, tingling, weakness, 441–442
- for left wrist drop, 456–457
- for lower back pain, 323, 368–369, 399–400
- for neck pain, 350–351, 366–367, 372–373, 389–390, 434–435
- for numbness, 402–403, 447–448
- for pacemaker placement, 454
- for peroneal neuropathy, 376
- for radiculopathies, 385–386
- for right calf atrophy, 392–393
- for right foot drop, 331–332
- for right hand numbness, tingling, 408–409
- for right upper extremity weakness, 431–432
- for sciatic neuropathy, 343–347
- for sensorimotor dysfunction, 356–359
- for shoulder fracture-dislocation, 328–329
- for symmetric weakness, 395–397, 413–415, 426–428
- for ulnar neuropathy, 341, 383
- for upper extremity weakness, wasting, 437–438
- for weakness and numbness, 450–451, 464–465, 467–468, 470–471, 474–475, 477–478
- findings, range of, 320
- history of, 161
- insertional activity in, 162, 170–171, 184, 235
- on Kennedy disease, 239
- manifestations, of various pathophysiology, 202
- measurements, 169–170
- MEPP in, 171–172
- motor NCS and, 138–140, 161–162, 201
- MUAP
- assessment in, 162–163, 173
- 183–184
- duration in, 175–177, 284
- recruitment in, 165–166
- stability in, 178
- muscles in, 162, 310
- myopathies and, 254
- myotonic potentials in, 191
- pitfalls of, 281–282
- provoked activity in, 170, 184
- in radiculopathies, 240
- resting phase of, 171, 184–185
- spontaneous activity in, 162, 170–171, 184–185, 202
- study
- of axon loss, 215–216
- of calcinosis cutis, 299
- in encounter, 309–312
- on hereditary polyneuropathies, 251
- of iatrogenic pneumothorax, pneumoperitoneum, 298
- of LEMS, 253–254
- in lesion severity assessment, 218
- lessening discomfort associated with, 310–312
- of lumbosacral plexus, 245–246
- of myasthenia gravis, 253
- of plexopathies, 242–245
- in UMN disorders, 235
- voluntary activity in, 162, 170, 173
- needle recording electrodes, 178–179
- concentric, 179–180
- dimensions, areas of, 179
- monopolar, 180
- negative AUC
- amplitude and, 104–105, 132
- in EDX laboratory, 105
- measurement of, 104–105
- negative charge, of electrons, 6
- negative peak voltage, 25
- negative phase duration, 109
- negative sink, 91–92
- Nernst equation, 55–56
- nerve. *See also* sensory nerve action potential
- accessory deep peroneal, 269–270
- activation time, 106
- conduction
- time, 106–107
- velocity, 107
- motor, 51, 85
- preterminal, 242–243
- transfer, 227
- trunk, 65–66, 228
- nerve conduction studies (NCS). *See also* motor NCS; sensory NCS; surface recording electrodes
- abnormalities, 318
- age-related issues in, 260–261
- axon disruption in, 137–138
- bipolar, referential recordings of, 88
- concepts, principles of, 85–86
- of cool limbs, 258–259
- in EMG laboratory, 85, 93
- exercise
- for bilateral hand numbness, tingling, 332–334, 359–361
- for bilateral lower extremity weakness, 429
- for bilateral upper extremity weakness, 410–411, 421–422
- for carpal tunnel syndrome, 324–326, 347–348, 351–353
- for diffuse numbness, weakness, 404–405
- for diffuse upper extremity weakness, sensory loss, 460–461
- for distal left upper extremity sensory, motor abnormalities, 442–444
- for generalized weakness, 416–418

- for left foot numbness, burning, 378–380
- for left hand atrophy, 457–459
- for left hip pain, 335–337
- for left upper extremity pain, tingling, weakness, 439–441
- for left wrist drop, 455–456
- for lower back pain, 322–323, 368, 398–399
- for neck pain, 349–350, 364–366, 370–372, 387–389, 433–434
- for numbness, 401–402, 445–447
- or bilateral lower extremity weakness, 429
- for pacemaker placement, 452–454
- for peroneal neuropathy, 374–375
- for radiculopathies, 384–385
- for right calf atrophy, 391–392
- for right foot drop, 330–331
- for right hand numbness, tingling, 407–408
- for right upper extremity weakness, 431
- for sciatic neuropathy, 342–345
- for sensorimotor dysfunction, 355–356, 358
- for shoulder fracture-dislocation, 327–328
- for symmetric weakness, 394–395, 412–413, 425–426
- for ulnar neuropathy, 339–340, 381–382
- for upper extremity weakness, wasting, 436–437
- for weakness and numbness, 448–450, 463–464, 466–467, 469–470, 472–477
- explaining, to patient, 308–309
- findings of, 319
- focal demyelination in, 137–138
- focal DMCB and, 129
- focal DMCS, 126
- with indwelling medical devices, 294–295
- in intraspinal canal disorders, 236
- in lesion localization, 137, 140
- limbs studied in, 309
- of lumbosacral plexus, 245
- manifestations, timing of, 135–136
- mixed, 93, 121–122
- performed first, during encounter, 309
- pitfalls of, 281
- routine, in LEMS, 253
- routine, in myasthenia gravis, 252
- surface recording electrodes in, 87
- technician, 306
- in UMN, 235
- nerve fiber, 52–53, 99–100, 111.
See also fascicles; myelin
- nerve injuries
 - connective tissue in, 224
 - Seddon classification system for
 - axonotmesis in, 222
 - neurapraxia in, 221–222
 - neurotmesis in, 222
 - Sunderland classification system for, 222
 - grade 1, 222
 - grade 2, 222–223
 - grade 3, 223
 - grade 4, 223
 - grade 5, 223–224
 - grade 6, 224
 - surgical intervention in, 224–225
 - types of, 227–228
 - compartment syndrome, 232
 - compression injuries, 228–231
 - ischemic injuries, 231
 - stretch injuries, 228
 - traction injuries, 228
 - transection injuries, 231
- nerve stimulation
 - in motor NCS, 98–99
 - nonuniform DMCS and, 128
 - proximal median motor response to, 99
 - tibial, 142–144
- neural control, of muscle, 76
- CNS influence in, 76–77
- final common path in, 76
- muscle spindles in, 77
- neuralgic amyotrophy (NA), 439
- neurapraxia, 221–222
- neurogenic MUAP, 130–131, 176, 218, 243–245
- neurogenic recruitment
 - grades of, 320
 - grading, 197–198
 - MUAP in, 168–169, 197–198, 243–245
 - as pathological, 319
- neurological examination, 302
- neuromuscular junctions (NMJ), 68–71
 - degeneration, 137
 - disorders, 152, 251–252
 - LEMS as, 253–254
 - myasthenia gravis as, 252–253
 - in high frequency RNSS, 157
 - of muscle fibers, 80
 - transmission, 200, 205
 - disorders, SFEMG for, 206
 - safety factor of, 153
- neuromyotonia, 191–192
- neuronopathies, sensory, 251
- neurons, 50
 - fusimotor, 76
 - motor, 50–51, 146
 - resting, 57
 - sensory, 51–52
 - skeletofusimotor, 76
 - skeletomotor, 76
- neurotization, 227
- neurotmesis, 222
- neurotonic discharge, 192
- neurotransmitters, 68
- neutrons, 4–5
- NMJ transmission time, 107
- NMJs. *See* neuromuscular junctions
- nodal intussusception, 230
- nodal membrane segments, 63–64
- nodes, of Ranvier, 52
- noise, 35
- nonadhesive surface recording
 - electrodes, 89
- non-dissipative opposition, 23
- nongated ion channels, 54, 57–58
- non-inverting amplifiers, 46
- nonlinear phase characteristic, 40–41
- non-myopathic motor unit
 - disintegration disorders, 199–200
- nonorganic lesions, 318–319
- nonpathological causes, of low motor responses, 202
- nonuniform DMCS, 127–128
- normal control values, in EMG laboratory, 282
- notch filter, 40–41
- numbness. *See also* diffuse numbness and weakness; left foot numbness and burning; right hand numbness and tingling; weakness and numbness
 - exercise, 400, 445
 - EDX conclusion in, 403, 448
 - NCS in, 401–402, 445–447
 - needle EMG in, 402–403, 447–448
- Occupational Safety and Health Administration (OSHA), 290, 296
- Ohm, Georg Simon, 12
- Ohm's law
 - on AC, 23
 - current and, 15
 - in electricity, 12–13
 - reactance, resistance and, 33
 - voltage and, 15
- onset frequency, 165–166
- onset latency, 105–106, 112
 - changing sensitivity, to better identify, 282–283
- peak latency and, 117–118
- in SNAP, 116
- open circuit, 14–15

Index

- orthodromic conduction, 92–93
 orthodromic sensory NCS, 111, 114–116
 OSHA. *See* Occupational Safety and Health Administration
 output voltage, 17
- paced fiber, 193
 pacemaker placement, exercise, 452
 EDX conclusion in, 454
 NCS in, 452–454
 needle EMG in, 454
 pacing fiber, 193
 parallel circuits, 13–14
 parallel DC circuits, 18–20
 parallel resistors, 19–20
 pathophysiology, 105, 133–134, 202, 214–215
 Pauli exclusion principle, 5–6
 peak latency, 112, 117–118
 peak voltage, 25, 37
 peak-to-peak
 amplitude, 113, 173–175
 voltage, 25
 pennate muscle, 80
 perineurium, 65
 period, of wave, 24–25
 peripheral nerve injuries
 demographics of, 213
 proper initial management of, 213
 types of, 213
 peripheral nervous system (PNS), 50–52, 138–140
 peripheral neuropathies
 acquired axon loss polyneuropathies as, 247–248
 EDX testing for, 246
 focal, 246–247
 types of, 246
 peroneal neuropathy. *See also* accessory deep peroneal nerve
 deep, 364
 exercise, 361–363, 374
 EDX conclusions of, 364, 376–378
 NCS in, 374–375
 needle EMG in, 376
 left common, 376–378
 right superficial, 364
 peroneal-EDB, 285
 phases, of MUAP, 177–178, 195
 phosphocreatine, 78
 phospholipid layers, 49
 photons, 7, 9
 physiologic temporal dispersion, 113–114, 131
 Piper, H., 85
 pitfalls
 age-related issues, 260–261
 body habitus-related issues, 261–262
 clinical biases as, 285
 conceptual, 282–286
 of EDX providers, 257, 270
 of EMG machine, 276
 impedance, between signal source, surface recording electrode as, 286
 of NCS, 281
 of needle EMG, 281–282
 of recording electrodes, 270–271
 of stimulation, 271–281
 studying cool limbs, 257–260
 technical, 270
 time constraints as, 284
 plexopathies
 of brachial plexus, 242–245
 of cervical plexus, 242
 EDX examination of, 241–242
 of lumbosacral plexus, 245–246
 needle EMG studies of, 242–245
 neurogenic MUAP in, 243–245
 sensory NCS in, 241–242
 pneumoperitoneum, 298–299
 PNS. *See* peripheral nervous system
 point localization, 317
 polyneuropathies
 acquired axon loss, 247–248
 acquired demyelinating, 248–249
 AIDP as, 249
 CIDP as, 249–250
 EDX testing for, 248
 hereditary, 250–251
 length-dependent, 247
 mixed, 250
 sensory NCS in, 248
 positive dip, of E1 electrode, 97–98, 270–271
 positive sharp wave form
 of fibrillation potential, 186, 188
 insertional, 188
 postexercise exhaustion, 155–156
 postexercise facilitation, 155–156
 postganglionic lesions, 140
 post-poliomyelitis syndrome, 237–238
 postsynaptic folds, 70
 postsynaptic membrane, 68
 postsynaptic membrane
 depolarizations, 71–72
 postsynaptic region, 70–71
 potential difference, 10
 power loss equation, 29–30
 power stroke, 75
 preamplifier, 87
 precautions, of OSHA, 296
 prepatterning, 70
 presynaptic membrane, 68
 presynaptic region, 69
 preterminal nerves, of brachial plexus, 242–243
 primary endings, in muscle fibers, 77
 primary synaptic cleft, 70
 progressive proximal spinal and bulbar muscular atrophy. *See* Kennedy disease
 propagation. *See also* action potential
 propagation
 bidirectional, 74
 continuous, 61
 protons, 4–5, 7
 provoked activity, in needle EMG, 170, 184
 proximal conduction time, 147
 proximal latency, 105
 proximal lesion, 147–148
 proximal median motor response
 MGA and, 266–267
 to nerve stimulation, 99
 proximal stimulation site, 108, 111–112
 proximal tibial motor response, to motor NCS, 100
 proximally-located DMCB, 201
 proximodistal axon advancement, 183, 196, 220
 proximodistal axon regeneration, 219–220
 pseudofacilitation, 155–157
- quantal content, 69, 71
 quantification, of fibrillation potentials, 187
 quantum, 69
 quarks, 5
- radiculopathies, 134. *See also* neck pain
 EDX study of, 240
 EDX testing of, 241
 exercise
 NCS in, 384–385
 needle EMG in, 385–386
 as intraspinal canal disorders, 239–241
 motor NCS and, 239–240
 MUAP duration in, 240
 needle EMG in, 240
 raindrops striking a tin roof, 186–187
 rapsyn, 70
 RC circuits
 capacitors in, 37–39
 EDX providers and, 38
 filters in, 35–36
 mixed signal in, 37–38
 RCA. *See* Riche-Cannieu anastomosis
 reactance, 23
 capacitive, 36
 Ohm's law and, 33
 reciprocals, 19

- recording electrodes. *See also*
 electrodes; motor NCS; needle
 recording electrodes; surface
 recording electrodes
 APs of, 90–91
 for MUAP, 179–180
 pitfalls of, 270–271
 in sensory NCS, 115
- recruitment. *See also* motor unit action
 potential; neurogenic
 recruitment
 early, 169, 199–200
 frequency, 165–166
 maximal temporal, 168–169
 motor unit, 164–169
 ratio, 166, 168
 full interference pattern in, 168
 rule of fives in, 166–167
 spatial, temporal, 169, 198–199
 UMN, 198–199
- red flags, 248
- reduced interference pattern, 197
- reduced temperature, in EDX study,
 258–260
- reference electrode, 87
- referential recordings, 88
- regenerative distance, 225–226
- regional localization, 317
- reinnervation, 183, 194–195
 aberrant, 223
 via collateral sprouting, 195–196,
 201, 218–220
 determining potential for, 220–221
 mechanisms of, 218, 220
 via proximodistal axon
 advancement, 196, 220
 via proximodistal axon regeneration,
 219–220
 sensory receptor, 220
- relative refractory period, 58–59
- relatively abnormal, 284
- Remak bundle, 52
- remyelination, 221
- repeater F waves, 147
- repetitive nerve stimulation (RNS),
 152–153
- repetitive nerve stimulation studies
 (RNSS), 152–153
 of cool limbs, 259–260
 high frequency, 157
 in EMG laboratories, 157
 Lambert test in, 157–158
 in NMJ transmission disorders,
 157
 pseudofacilitation in, 157
 technique, 157–158
 with indwelling medical devices, 295
 for LEMS, 253
 low frequency, 153
- abnormal, 156
 baseline train in, 154
 distal muscles in, 154
 postexercise facilitation,
 exhaustion in, 155–156
 pseudofacilitation in, 155–156
 technical errors in, 156–157
 technique of, 154–155
 for myasthenia gravis, 252–253
- repolarization
 absolute, relative refractory period
 in, 58–59
 depolarization and, 57–58
 phase, 57
- resistance, 23
 amplifier, 44
 of circuit, 15–16, 19–20
 in electricity, 11–12
 least, 18
 Ohm's law and, 33
 of skin, 44, 293
 of tissue, 291
 total membrane, 60
 voltage and, 15–16, 18
- resistors, 15–17. *See also* RC circuit
 frequency-dependent, 38
 frequency-independent, 36
 parallel, 19–20
- response dispersion, 109
- resting membrane potential (RMP), 43,
 55–56
- resting neuron, 57
- resting phase, of needle EMG, 171,
 184–185
- reversals
 in AC, 23, 36
 stimulator, 279
- ribbon pair leadwire, 46
- Riche-Cannieu anastomosis (RCA),
 268–269
- right calf atrophy, exercise, 390
 EDX study conclusion in, 394
 NCS in, 391–392
 needle EMG for, 392–393
- right foot drop, exercise, 329–330
 EDX study conclusion in,
 332
 NCS in, 330–331
 needle EMG in, 331–332
- right hand numbness and tingling,
 exercise, 407
 EDX study conclusion in, 409
 NCS in, 407–408
 needle EMG in, 408–409
- right superficial peroneal neuropathy,
 364
- right upper extremity weakness,
 exercise, 430–431
 EDX study conclusion in, 432
- NCS in, 431
 needle EMG in, 431–432
- rigor mortis, 76
- RMP. *See* resting membrane potential
- RMS. *See* root-mean-square voltage
 value
- RNS. *See* repetitive nerve stimulation
- RNSS. *See* repetitive nerve stimulation
 studies
- roll-off slope, 39
- root-mean-square (RMS) voltage value,
 25–26
- Rule of 20, 225
- rule of fives, in recruitment ratio, 166–167
- safe current limits, 293
- safety factor, 71
 of AP propagation, 125–126
 of NMJ transmission, 153
- safety issues
 of bleeding, 295–296
 of calcinosis cutis, 299
 in EDX laboratory, 290
 electrical injury and, 290–293
 of iatrogenic pneumothorax,
 pneumoperitoneum, 298–299
 of indwelling medical devices,
 293–295
 of transmission, of infection,
 296–298
- saltatory conduction, 61, 63–64,
 123
- sarcolemma, 73–74
- sarcomeres, 74
- sarcoplasm, 73
- sarcoplasmic reticulum, 74
- satellite potential, MUAP and, 196
- Schwann cells, 52, 123–124, 131
- sciatic neuropathy. *See also* right foot
 drop
 exercise, 342
 EDX study conclusion in, 344
 NCS in, 342–345
 needle EMG in, 343–347
- secondary clefts, 70
- secondary endings, in muscle fibers,
 77
- Seddon classification system
 axonotmesis in, 222
 neurapraxia in, 221–222
 neurotmesis in, 222
- selective ionic permeability, 53, 56
- semiconductors, 8–9
- sensitivity
 changing, to better identify onset
 latency, 282–283
 of EMG machines, 283
 gain and, 282
 sweep speed and, 283–284

Index

- sensorimotor dysfunction, exercise, 354
 EDX study conclusion in, 357
 motor NCS in, 354–355
 NCS in, 355–356, 358
 needle EMG in, 356–359
 sensory domains, 134
 sensory NCS, 92–93
 abbreviations for, 320–321
 advantages, disadvantages of, 119, 135
 amplitude in, 113–114
 antidromic, orthodromic, 111, 114–116
 conduction velocity in, 114, 118–119
 digital, 114
 in DRG, 138
 E1, E2 electrodes in, 113
 E1 electrode misplacement in, 112
 in EDX examination, 111
 in EMG laboratories, 113
 filtering in, 119–120
 focal demyelination in, 134
 interelectrode distance in, 120–121
 latency in, 116
 lesions in, 134
 in localization, of postganglionic lesions, 140
 manifestations, of pathology, pathophysiology, 133–134
 measurement in, 112–113
 in plexopathies, 241–242
 on PNS, 139–140
 in polyneuropathies, 248
 proximal stimulation site in, 111–112
 recording electrodes in, 115
 technique, 111–112
 sensory nerve action potential (SNAP), 111, 116, 135
 sensory nerve fibers, 52–53, 111
 sensory neuronopathies, 251
 sensory neurons, 51–52
 sensory receptor reinnervation, 220
 sensory response
 amplitude, 135, 216
 axon loss and, 135–136
 value of, lesion severity and, 218
 series circuits, 13–14
 series DC circuits, 14–18
 SFEMG. *See* single fiber EMG
 shock artifact. *See* stimulus
 short circuit, 15
 shoulder fracture-dislocation, exercise, 327
 EDX study conclusion in, 329
 NCS in, 327–328
 needle EMG in, 328–329
 signal
 clean, 46
 common, 47
 desired, undesired, in EMG machine, 33
 difference, 46
 in EDX study, 34–35
 mixed, 37–38
 source, 286
 signal source generator, 46
 signal-to-noise ratio (SNR), 35, 47, 277
 silent contractures, 184
 single fiber EMG (SFEMG), 204, 207–208
 criteria, for assessment, 206
 for muscle fiber APs, 204–205
 needle electrodes, 204–205
 for NMJ transmission disorders, 206
 utility of, 206
 single-phase power, 28
 sink, 91–92
 sixth-degree injury, 224
 60 Hz power artifact, AC signal of, 276–278
 skeletofusimotor neurons, 76
 skeletomotor neurons, 76
 skin
 impedance, 273
 preparation, 44–45, 88–89
 resistance, 44, 293
 in transmission, of infection, 298
 SMA-3. *See* spinal muscular atrophy type 3
 SNAP. *See* sensory nerve action potential
 snap-crackle-pop, 170
 SNR. *See* signal-to-noise ratio
 solid angle analysis, 92
 spatial recruitment, 169, 198–199
 spike form, of fibrillation potential, 185–186
 spinal cord
 level, motor response from, 138
 myotome and, 138
 spinal muscular atrophy type 3 (SMA-3), 238–239
 spiral groove, DMCB and, 128
 spontaneous activity, in needle EMG, 162, 170–171, 184–185, 202
 standard precautions, 296
 staphylococcus aureus, 298
 static, 6
 static electricity, 4, 7–8
 steady state, 33
 stimulating electrodes, 93–94
 stimulation. *See also* nerve stimulation;
 repetitive nerve stimulation
 studies
 above lesion, 131
 below lesion, 131
 excessive, 275–276
 machine maximum, 276
 pitfalls of, 271–281
 sites
 of DMCB, 130
 proximal, 108, 111–112
 submaximal, 274–275, 279
 stimulators
 constant current, 44, 272
 constant voltage, 44, 272
 current and, 43–44
 depolarization by, 43–44
 on EMG machines, 44
 reversal of, 279
 skin resistance to, 44
 stimulus. *See also* nerve stimulation
 lead, 89, 93, 276
 maximum response to, 93
 spread, 276
 strength, 89–90, 93
 supramaximal, 93
 stimulus artifact, 271–272
 reduction, 272–273
 anode rotation, about cathode in, 273–275
 final options in, 274
 future of, 274
 stopband filter, 40. *See also* notch filter
 stretch injuries, 228
 submaximal stimulation, 274–275, 279
 Sunderland classification system, 222–223, 225–226
 grade 1, 222
 grade 2, 222–223
 grade 3, 223
 grade 4, 223
 grade 5, 223–224
 grade 6, 224
 supervision, of EDX study, 306–307
 supine patient, in H reflex study, 142
 supraclavicular plexus, 243
 supramaximal stimulus, 93
 surface recording electrodes
 adhesive, nonadhesive, 89
 basic technique of, 88–90
 impedance, between signal source and, 286
 in NCS, 87
 proper placement of, 87–88
 response to, 89–90
 surface stimulating electrodes, 88
 surgical intervention
 approach, to axon loss in, 225–226
 in nerve injuries, 224–225
 surgical interventions, major, 226–227
 suturing, end-to-end, 226–227
 sweep speed, 283–284
 switches, 15
 switchyards, 27

- symmetric weakness, exercise, 394, 412, 424–425
 NCS in, 394–395, 412–413, 425–426
 needle EMG in, 395–397, 413–415, 426–428
- synapses, 68
- synaptic space, 68–69
- synchronized slowing. *See* uniform DMCS
- synchrony, 103
- synthesized ACh, 69
- tail, 75
- technical errors
 in H wave testing, 143–144
 in low frequency RNSS, 156–157
- temporal dispersion
 motor NCS and, 131
 physiologic, 99–100, 113–114, 131
- temporal recruitment, 169, 198–199
- terminal boutons, 68–69
- terminal branch conduction time, 107
- terminal cisternae, 74
- terminal positive phase, 91
- territorial distribution, 51
- thick filaments, 75–76
- thin filaments, 75–76
- three-phase power, 28–29
- threshold time, 106
- tibial nerve stimulation, in H reflex study, 142–144
- tibial response, amplitude, 100
- time
 backfire, 146–147
 of conduction velocity, 107
 constant
 in capacitors, 22, 60
 myelin sheath and, 125
 constraints, as pitfalls, 284
 cursors, on EMG machines, 285–286
 difference, 277–278
 discharge, 125
 distal latency and, 106–107
 of muscle activation, 107
 of nerve activation, 106
 of NMJ transmission, 107
 of proximal conduction, 147
 of terminal branch conduction, 107
 threshold, 106
 tissue transit, 106
- tissue
 resistance of, 291
 transit time, 106
- TMP. *See* transmembrane potential
- total membrane capacitance, 60
- total membrane resistance, 60
- tourniquet paralysis, 230
- traction injuries, 228
- trailing source current, 91
- transection injuries, 231
- transformers, 27–31
- transient axonal conduction block, 131–132, 216
- transistor batteries, 11
- transition band, 39
- transmembrane current, 60
- transmembrane potential (TMP), 43, 53, 185. *See also* resting membrane potential
 cell membrane and, 60
 equilibrium potential and, 55–56
 ion movement and, 56
 of resting neuron, 57
- transmission feeders, 27
- transverse current, 62
- transverse tubules, 74
- trapezius muscle, 299
- triad, 74
- triboelectric effect, 6
- trigger line, of MUAP, 176
- triggering potential, of muscle fiber APs, 205
- tropomyosin, 74–75
- troponin, 74–75
- turns, of MUAP, 177–178, 195
- 20:20 rule, 100
- twisted pair leadwire, 46
- ulnar motor response, 96–97, 129
- ulnar neuropathy, 263, 266–267.
 See also neck pain
 exercise, 338, 381
 EDX study conclusion in, 341–342, 383–384
 NCS in, 339–340, 381–382
 needle EMG in, 341, 383
- ulnar-to-median anastomosis, 268
- ultrahigh voltage, 29
- UMN. *See* upper motor neuron
- undesired signal, 33, 35, 45–46. *See also* noise
- uniform DMCS, 126–127
- unipennate muscle, 80
- universal precautions, 296
- upper extremity weakness and wasting, exercise, 436
 EDX study conclusion in, 439
 NCS in, 436–437
 needle EMG in, 437–438
- upper motor neuron (UMN), 50, 76.
 See also intraspinal canal disorders
- ALS and, 238
- disorders, 235–236
 MUAP recruitment in, 235–236
 NCS in, 235
 needle EMG in, 235
- recruitment, 198–199
- upper plexus, 243–244
- vacuum tube, 42
- velocity. *See* conduction velocity; drift velocity
- verbal informed consent, 308–309
- vertical resolution, 42–43, 283
- vesicles, of ACh, 69, 71–72, 152–153
- VGCCs. *See* voltage-gated calcium channels
- VGKCs. *See* voltage-gated potassium channels
- VGNCs. *See* voltage-gated sodium channels
- voltage. *See also* constant voltage stimulators; direct current; Goldman-Hodgkin-Katz voltage equation; Kirchhoff's voltage law; root-mean-square voltage value
 in AC, 23–24
 in batteries, 10–11, 18
 in capacitors, 37
 charge separation and, 22
 in circuit, 10, 17
 dividers, as resistors, 16–17
 in EDX medicine, 10
 in electricity, 10–11
 EMF and, 12
 in EMG laboratory, 46
 low, ultrahigh, 29
 negative peak, 25
 Ohm's law and, 15
 output, 17
 peak, 25, 37
 peak-to-peak, 25
 resistance and, 15–16, 18
 ultrahigh, 29
- voltage-gated calcium channels (VGCCs), 68, 253
- voltage-gated channels, 54
- voltage-gated potassium channels (VGKCs), 54, 58
- voltage-gated sodium channels (VGNCs), 54, 58–59
 activation gate of, 258
 in bidirectional propagation, 74
 in depolarization, 61
- volume conduction, 90–92
- voluntary activity
 in MUAP assessment, 193–194
 in needle EMG, 162, 170, 173
- Wallerian degeneration, 123–124, 131, 134
 in axon disruption, 137–138
 conduction block in, 216
 at lesion site, 137–138

Index

water, flow of, 12–14, 18–19	weakness and numbness, exercise, 448, 463, 465, 468, 472, 475	Weichers-Johnson syndrome, 170–171
wave, period of, 24–25	EDX conclusion in, 451–452, 465, 468, 471–472, 475, 478	weight, 262
weakness. <i>See</i> bilateral lower extremity weakness; bilateral upper extremity weakness; generalized weakness; symmetric weakness; upper extremity weakness and wasting	NCS in, 448–450, 463–464, 466–467, 469–470, 472–477	X-linked recessive bulbospinal neuronopathy, 239
	needle EMG in, 450–451, 464–465, 467–468, 470–471, 474–475, 477–478	zinc-carbon batteries, 11
		Z-line, 75